Feb. 26 at 12:32 PM
$ATAI Releases Major Clinical Pipeline News 📰
ATAI Life Sciences announced positive topline results from its exploratory Phase 2a clinical trial evaluating EMP-01 for the treatment of social anxiety disorder.
Trial Overview and Key Findings
👉🏽Randomized, double-blind, placebo-controlled exploratory trial
👉🏽EMP-01 demonstrated encouraging efficacy signals in patients with social anxiety disorder
👉🏽Treatment was reported to be generally well tolerated
Strategic Importance
👉🏽Supports continued advancement of EMP-01 into future clinical trials
👉🏽Strengthens ATAI’s position in psychedelic-inspired therapeutics
👉🏽Reinforces the company’s focus on innovative psychiatric treatments
EMP-01 remains in early-stage development, but the positive Phase 2a data marks an important step forward in ATAI’s efforts to expand treatment options for social anxiety disorder.
Communicated Disclaimer : https://bit.ly/3OCJhol
Sector Peers:
$GHRS $HELP $RLMD $SILO
